|
1
|
American Cancer Society: Facts &
Figures-2016. American Cancer Society; Atlanta, GA: 2016
|
|
2
|
Fodde R, Smith R and Clevers H: APC,
signal transduction and genetic instability in colorectal cancer.
Nat Rev Cancer. 1:55–67. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fodde R, Edelman W, Yang K, Van Leeuwen C,
Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, et al: A
targeted chain termination mutation in the mouse Apc gene results
in multiple intestinal tumors. Proc Natl Acad Sci USA. 91:pp.
8969–8973. 1994; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oshima M, Oshima H, Kitagama K, Kobayashi
M, Itakura C and Takata M: Loss of Apc heterozygosity and abnormal
tissue building in nascent intestinal polyps in mice carrying a
truncated Apc gene. Proc Natl Acad Sci USA. 92:pp. 4482–4486. 1995;
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katdare M, Kopelovich L and Telang N:
Efficacy of chemopreventive agents for growth inhibition of Apc
[+/−] 1638NCOL colonic epithelial cells. Int J Mol Med. 10:427–432.
2002.PubMed/NCBI
|
|
6
|
Telang NT, Li G and Katdare M: Prevention
of early onset familial/hereditary colon cancer: New models and
mechanistic biomarkers (review). Int J Oncol. 28:1523–1529.
2006.PubMed/NCBI
|
|
7
|
Telang N and Katdare M: Combinatorial
prevention of carcinogenic risk in a model for familial colon
cancer. Oncol Rep. 17:909–914. 2007.PubMed/NCBI
|
|
8
|
Telang N and Katdare M: Novel cell culture
model for prevention of carcinogenic risk in familial polyposis
syndrome. Oncol Rep. 21:1017–1021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Telang N and Katdare M: Putative cancer
initiating stem cells in a model for familial adenomatous polyposis
(FAP) syndrome. Int J Mol Med. 30 Suppl 1:S102012.
|
|
10
|
Telang N: Preventive efficacy of the
non-steroidal anti-inflammatory drug Sulindac on cell culture
models for genetically predisposed early onset colon cancer. Int J
Mol Med. 34 Suppl 1:S152014.
|
|
11
|
Beazer-Barkley Y, Levy DB, Moser AR, Dove
WF, Hamilton SR, Vogelstein B and Kinzler KW: Sulindac suppresses
tumorigenesis in the Min mouse. Carcinogenesis. 17:1757–1760. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jacoby RF, Siebert K, Cole CE, Kelloff G
and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent
preventive and therapeutic agent in the Min mouse model of
adenomatous polyposis. Cancer Res. 60:5040–5044. 2000.PubMed/NCBI
|
|
13
|
Jacoby RF, Cole CE, Tutsch F, Newton MA,
Kelloff G, Hawk ET and Lubet RA: Chemopreventive efficacy of
combined piroxicam and difluoromethylornithine treatment on Apc
mutant Min mouse adenoma, and selective toxicity against Apc mutant
embryos. Cancer Res. 60:1864–1870. 2000.PubMed/NCBI
|
|
14
|
Baron JA, Cole BF, Sandler RS, Haile RW,
Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R,
Burke CA, et al: A randomized trial for aspirin to prevent
colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Girdiello FM, Hamilton SR, Krush AJ,
Piantadosis S, Hylind LM, Cellano P, Brooker SV, Robinson CR and
Offerhans GL: Treatment of colonic and rectal adenomas with
Sulindac in familial adenomatous polyposis. N Engl J Med.
328:1313–1316. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stienbeck G, Lynch PM, Phillips RK,
Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y,
Fujimura T, et al: The effect of Celecoxib, a cyclooxygenase-2
inhibitor, in familial adenomatous polyposis. N Engl J Med.
342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta RA and Dubois RN: Colorectal cancer
prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev
Cancer. 1:11–21. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Solomon SD, McMurray JJ, Pfeffer MA,
Wilters J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and
Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study
Investigators, : Cardiovascular risk associated with Celecoxib in a
clinical trial for colorectal adenoma prevention. N Engl J Med.
352:1071–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bresalier RS, Sandler RS, Quan H,
Bolognese JA, Oxenius B, Horgam K, Lines C, Ridell R, Morton D,
Lanas A, et al: Cardiovascular events associated with rofecocixb in
a colorectal adenoma chemoprevention trial. N Engl J Med.
352:1092–1102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:pp. 10158–10163. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumor
growth in immunedeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ricci-Vitiani L, Lombardi DG, Pillozi E,
Biffoni M, Todaro M, Peschele C and De Maria R: Identification and
expansion of human colon cancer initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka T, Kohno H, Suzuki R, Hata K, Sugie
S, Niho N, Sakano K, Takahashi M and Wakabayashi K: Dextran sodium
sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+)
mice: Inflammatory stimuli by Dextran sodium sulfate results in
development of multiple colonic neoplasms. Int J Cancer. 118:25–34.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Basudhar D, Somsudaram V, Glyn S, Ridnour
LA, Cheng RY and Wink DA: Regulatory effects of NOS2-COX2 in breast
progression in tumor microenvironment. Int J Mol Med. 38 Suppl
l1:S812016.
|
|
26
|
Katdare M, Osborne M and Telang NT: Soy
isoflavone genistein modulates cell cycle progression and induces
apoptosis in HER-2/neu oncogene expressing human breast epithelial
cells. Int J Oncol. 21:809–815. 2002.PubMed/NCBI
|
|
27
|
Boolbol SK, Dannenberg AJ, Chadburn A,
Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin
ML, DeCosse JJ and Bertagnolli MM: Cyclooxygenase-2 over-expression
and tumor formation are blocked by Sulindac in a murine model for
familial adenomatous polyposis. Cancer Res. 56:2556–2560.
1996.PubMed/NCBI
|
|
28
|
Mahmood NN, Boolbol SK, Dannenberg AJ,
Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A and
Bertagnolli MM: The sulfide metabolite of Sulindac prevents tumors
and restores enterocyte apoptosis in a murine model for familial
adenomatous polyposis. Carcinogenesis. 19:87–91. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mahmood NN, Bilinski RT, Churchill MR,
Edelmann W, Kucherlapati R and Bertagnolli MM: Genotype phenotype
correlation in murine Apc mutation: Differences in enterocyte
migration and response to sulindac. Cancer Res. 59:353–359.
1999.PubMed/NCBI
|
|
30
|
Williams CS, Goldman AP, Sheng H, Morrow
JD and Dubois RN: Sulindac sulfide, but not Sulindac sulfone,
inhibits colorectal cancer growth. Neoplasia. 1:170–176. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen KL, Pan F, Jiang H, Chen JF, Pei L,
Wie FW and Liang HJ: Highly enriched CD133(+)CD44(+) stem-like
cells with CD133(+)CD44(high) metastatic subset in HCT116 colon
cancer cells. Clin Exp Metastasis. 28:751–763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang C, Xie J, Guo J, Manning HC, Gore JC
and Gou N: Evaluation of CD44 and CD133 as cancer stem cell markers
for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou JY, Chen M, Ma L, Wang X, Chen YG and
Lui SL: Role of CD44(high)/CD133(high) HCT-116 cells in the
tumorigenesis of colon cancer. Oncotarget. 7:7657–7666. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Greenspan EJ, Nichols FC and Rosenberg DW:
Molecular alterations associated with Sulindac-resistant colon
tumors in ApcMin/+ mice. Cancer Prev Res (Phila). 3:1187–1197.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zeilstra J, Joosten SP, Dokter M, Verwiel
E, Spaargaren M and Pals ST: Deletion of the WNT target and cancer
stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal
tumorigenesis. Cancer Res. 68:3655–3661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoffmeyer K, Raggioli A, Rudolf S, Anton
R, Hierholzer A, Del Valle I, Hein K, Vogt R and Kemlar R:
Wnt/β-catenin signaling regulates telomerase in stem cells and
cancer cells. Science. 336:1549–1554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nasuni I, Seimiya H and Tsuruo T:
Telomerase inhibition, telomere shortening, and senescence of
cancer cells by tea catechins. Biochem Biophys Res Commun.
249:391–396. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ramchandran C, Fonseca HB, Jhabvala P,
Escalon EA and Melnick SJ: Curcumin inhibits telomerase activity
through human telomerase reverse transcritpase in MCF-7 breast
cancer cell line. Cancer Lett. 184:1–6. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jagadeesh S, Kyo S and Banerjee PP:
Genestein represses telomerase activity via both transcriptional
and posttranslational mechanisms in human prostate cancer cells.
Cancer Res. 66:2107–2115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arndt GM and MacKenzie KL: New prospects
for targeting telomerase beyond the telomere. Nat Rev Cancer.
16:508–524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lobo NA, Shimono Y, Qian D and Clarke MF:
The biology of cancer stem cells. Annu Rev Cell Dev Biol.
23:675–699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Telang N: Putative cancer initiating stem
cells in cell culture models for molecular subtypes of clinical
breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI
|
|
44
|
Telang N: Growth inhibitory efficacy of
natural products in a model for triple negative molecular subtype
of clinical breast cancer. Biomed Rep. 7:199–204. 2017.PubMed/NCBI
|
|
45
|
Nguyen PH, Giraud J, Staedel C,
Chambonnier L, Dubus P, Cheveret E, Boeuf H, Gauthereau X, Rousseau
B, Fevre M, et al: All-trans retinoic acid targets gastric cancer
stem cells and inhibits patient-derived gastric carcinoma tumor
growth. Oncogene. 35:5619–5628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Roife D, Dai B, Kang Y, Perez MVR, Pratt
M, Li X and Fleming JB: Ex Vivo testing of patient-derived
xenografts mirrors the clinical outcome of patients with pancreatic
ductal adenocarcinoma. Clin Cancer Res. 22:6021–6030. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Crespo M, Vilar E, Tsai SY, Chang K, Amin
S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, et
al: Colonic organoids derived from human induced pluripotent stem
cells for modeling colorectal cancer and drug testing. Nat Med.
23:878–884. 2017. View Article : Google Scholar : PubMed/NCBI
|
